000504 Landfar Bio-medicine
- 6.72
- 0.000.00%
Landfar Bio-medicine News
Landfar Bio-medicine: 2024 Interim Performance Forecast
Even After Rising 17% This Past Week, Landfar Bio-medicine (SZSE:000504) Shareholders Are Still Down 59% Over the Past Three Years
[BT Financial Report Analysis] Landfar Bio-medicine Q1 2024 Report: Comprehensive Analysis of Assets, Liabilities, Profits and Cash Flow.
Landfar Bio-medicine (Stock Code: 000504) is an enterprise that specializes in the biomedical field, particularly with significant advantages in the cell industry. The company is committed to researching and applying advanced medical technologies such as stem cells, immune cells, and gene therapy, and has performed well in the commercialization of cell therapy products. With the deepening of domestic cell therapy research and the expansion of the market scale, Landfar Bio-medicine is expected to continue its leading position in this field. In addition, the company pays attention to the development of energy-saving and environmentally friendly industries, which is in line with the national green development strategy and promotes sustainable development. In the first quarter of 2024, Landfar Bio-medicine's capital...
Nanhua Biology (000504.SZ): Currently, beauty products such as essences, masks, and creams are still in their infancy
Gelonghui, May 24 | Nanhua Biology (000504.SZ) said on the investor interactive platform that the company currently has beauty products such as essences, masks, creams, etc. Currently, the main products on sale are EE18 Sturgeon Caviar Polypeptide Anti-Wrinkle Essence, EE18 Hydrolyzed Collagen Firming Kit, and EE18 Hydrolyzed Collagen Firming Mask. Currently, the beauty business is still in its infancy.
Landfar Bio-medicine Co., Ltd's (SZSE:000504) 30% Share Price Surge Not Quite Adding Up
Nanhua Biology (000504.SZ): The company does not yet have synthetic biotechnology
Gelonghui, May 8, 丨 Nanhua Biology (000504.SZ) said on the investor interactive platform that the company does not yet have synthetic biotechnology-related technology. The company's biomedical business is mainly cell storage, and also studies applications and services related to stem cells and immune cells. Among them, cell storage includes stem cell storage and immune cell storage. Applied research mainly includes stem cells to treat lung damage, mesenchymal stem cells treat gestational diabetes, basic and clinical research on stem cells to treat kidney disease, research on the molecular mechanisms of umbilical cord mesenchymal stem cell exosomes in skin damage repair, and umbilical cord mesenchymal stem cells
Landfar Bio-medicine Co., Ltd's (SZSE:000504) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 17% Last Week
Nanhua Biotech (000504.SZ): Net loss of 2.777 million yuan in the first quarter
Gelonghui, April 29丨Nanhua Biotech (000504.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 25.973,900 yuan, down 25.23% from the previous year; net profit attributable to shareholders of listed companies was 2.777 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 3.834 million yuan; basic earnings per share.
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 45% Price Jump
Landfar Bio-medicine (SZSE:000504) Adds CN¥439m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 46%
Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Nanhua Biotech (000504.SZ): Pre-loss of 19 million yuan to 28 million yuan in 2023
Gelonghui, January 26 | Nanhua Biotech (000504.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 19 million yuan to 28 million yuan, down 49.67 percent- 120.56% from the same period last year; net profit loss after deducting non-recurring profit and loss was 33.5 million yuan — 42.5 million yuan, down 45.33% -84.38% from the same period last year; basic earnings loss per share was 0.058 yuan/share — 0.085 yuan/share. Reasons for changes in performance: 1. During the reporting period, company cells
Landfar Bio-medicine Co., Ltd's (SZSE:000504) Market Cap Dropped CN¥396m Last Week; Private Equity Firms Bore the Brunt
The court froze 10.79% of the shares held by Shanghai Heping, the majority shareholder of Nanhua Biotech (000504.SZ)
Nanhua Biotech (000504.SZ) issued an announcement. The company recently received an issuance from China Securities Registration and Settlement Co., Ltd...
Nanhua Biotech (000504.SZ): Net profit for the third quarter was 9.4599 million yuan, up 681.72% year on year
On October 30, Gelonghui Biotech (000504.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 34.3262 million yuan, down 26.38% year on year; net profit attributable to shareholders of listed companies was 9.4599 million yuan, up 681.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 463443 million yuan; basic earnings per share of 0.0304 yuan.
Nanhua Biotech (000504.SZ): At present, it has developed the EE18 series of products, mainly essences, masks, creams, etc.
GLONGHUI September 18丨An investor asked Nanhua Biotech (000504.SZ) on the investor interactive platform, “How are the company's medical and aesthetic products progressing?” The company replied that the company has now developed the EE18 series of products, mainly essences, masks, creams, etc. In addition, the company also has some products under development.
Nanhua Biotech (000504.SZ): The reserve price for listing and transferring 2 of its own properties located in Haikou City, Hainan Province is 209.76 million yuan
On August 7, GLONGHUA BIOLOGICAL (000504.SZ) announced that in order to revitalize idle assets, optimize asset structure, and improve asset operation efficiency, Nanhua Biomedical Co., Ltd. plans to transfer 2 owned properties located in Haikou City, Hainan Province through public listing to Hunan Joint Property Exchange Co., Ltd. The company's current real estate transfer price will be based on the evaluation report issued by Shenzhen Pengxin Asset Assessment Land and Real Estate Appraisal Co., Ltd. (Pengxin Capital Assessment [2023] No. 187), and finally determined that the listing reserve price for the two owned properties was 209.776 million yuan.
Nanhua Biotech (000504.SZ)'s application to issue shares to a specific target was approved by the Shenzhen Stock Exchange
According to the Zhitong Finance App, Nanhua Biotech (000504.SZ) issued an announcement. On July 12, 2023, the company received the “Notice of Opinions from the Review Center on Nanhua Biomedical Co., Ltd.'s Application for Issuance of Shares to Specific Targets” issued by the Shenzhen Stock Exchange Listing Review Center. The issuance and listing review agency of the Shenzhen Stock Exchange reviewed the company's application documents for the issuance of shares to specific targets and found that the company met the issuance conditions, listing conditions, and information disclosure requirements. In the future, the Shenzhen Stock Exchange will report it to the China Securities Regulatory Commission to complete the relevant registration procedures in accordance with the regulations.
Landfar Bio-medicine Co., Ltd's (SZSE:000504) Last Week's 11% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
Landfar Bio-medicine (SZSE:000504) Is Carrying A Fair Bit Of Debt
Analysis
Price Target
No Data
